SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Leifras Co., Ltd. Engages in sport training, event and alliance & club activity support and healthcare activities. It provides services related to the organization and operations of sports schools and sports events for children and it also operate a robust social business sector, dispatching sports coaches to meet various community needs. The company was founded by Kiyotaka Ito on August 28, 2001 and is headquartered in Tokyo, Japan.

Leifras Co Ltd - ADR

LEIFRAS Co., Ltd. American Depositary Shares

Shares of LFS are surging, driven by excitement around its low float and potential for a short squeeze, reminiscent of other recent IPOs. Community members are actively discussing price targets and potential sympathy plays among Japanese stocks. Some traders caution about the risks associated with pump-and-dump schemes and recent IPOs, while others highlight positive financials and growth potential.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo is trending due to its upcoming earnings report, with the community split between bullish and bearish sentiment, while many express concerns about the company's high valuation and lack of current revenue. Community members are actively discussing potential price movements post-earnings, insider selling, and the overall viability of Oklo's long-term prospects in the nuclear energy sector.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

NBIS is trending amidst discussions about its earnings report and a new $3B Meta deal, though revenue slightly missed estimates, sparking mixed reactions. Community members are weighing the significance of capacity constraints and a potential ATM offering, while others debate the long-term prospects of AI infrastructure plays and compare NBIS to competitors like CRWV. Overall sentiment seems divided between bullish conviction in long-term growth and concerns about short-term volatility and dilution.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending as the stock price rises following news of a large, performance-based compensation package for its CEO, drawing comparisons to Tesla's executive compensation model. The community is bullish, anticipating further gains and discussing potential price targets, while also debating the company's long-term potential in the EV market amid increasing competition. Some investors are expressing concerns about the CEO's compensation plan relative to the company's current financial performance.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is trending as a bidding war with Novo Nordisk for Metsera intensifies, with community members speculating on potential outcomes and impacts on PFE's strategy in the growing weight-loss market. Some traders are noting high call option activity and significant volume, while others express skepticism, citing past performance and leadership concerns. Discussions also touch on the potential for sector rotation and the stock's undervaluation compared to competitors like Eli Lilly.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor ($OPEN) is trending amid discussions of a potential short squeeze, amplified by technical indicators and upcoming warrant distributions. The community is buzzing about perceived insider buying, particularly after the CEO's pledge to purchase $1M in stock, and speculating on a potential Robinhood partnership. Bullish investors are focused on the company's AI-driven turnaround strategy and the new CEO's vision for the real estate disruptor.

Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The firm is also involved in the development of small molecule inhibitors of galectin-3 and LOXL2. The company was founded by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye in 2011 and is headquartered in Boston, MA.

Galecto Inc

GLTO is trending due to a recent acquisition announcement, sparking significant interest and a massive price surge. The community is actively discussing the potential for a short squeeze, given the stock's low float and high short interest, with some speculating about further gains. Trading volume is exceptionally high as the stock experiences increased volatility.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is trending amid unconfirmed speculation that the company is in talks to be acquired, driving significant trading volume. The community is discussing potential buyout prices and who the acquirer might be, with some suggesting Merck due to existing partnerships. Short squeeze potential is also being debated given the stock's high short interest.

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Anavex Life Sciences Corporation

Anavex Life Sciences Corp

AVXL is trending amid anticipation for potential news regarding its Alzheimer's drug, Blarcamesine, as the company prepares for an oral explanation with the CHMP this week. Community discussions revolve around the potential approval outcomes and the impact on the stock, with some investors expressing concerns about short selling and manipulation while others remain optimistic about the drug's prospects in the European market given Blarcamesine's potential benefits over existing treatments.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending amid speculation of a potential bidding war and buyout offers, fueled by competitor Metsera's recent acquisition. Community chatter revolves around potential suitors, including non-pharma companies, and the possibility of a short squeeze. Some traders suggest the market is undervaluing VKTX given its promising pipeline and potential in the obesity and metabolic disorder space.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
